Predictive Genetic Testing & Consumer/Wellness Genomics Market Overview
The global Predictive Genetic Testing & Consumer/Wellness Genomics Market was valued at USD 5.74 billion in 2023 and is projected to reach USD 17.66 billion by 2032, growing at a CAGR of 13.33% over the forecast period 2024–2032.
This market is witnessing exponential growth, primarily fueled by increasing applications in personalized medicine, the integration of direct-to-consumer (DTC) genomic tests, and the rising consumer preference for proactive health management. Predictive genetic testing provides critical insights into an individual’s inherited health risks, enabling early detection and intervention, while wellness genomics promotes lifestyle optimization based on personal genetic profiles.
Get a Sample Report of Predictive Genetic Testing & Consumer/Wellness Genomics Market @ https://www.snsinsider.com/sample-request/2445
Predictive Genetic Testing & Consumer/Wellness Genomics Market Growth Drivers
- Rise in Preventive Healthcare Adoption
Consumers are increasingly adopting genetic testing to prevent chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. Predictive tests help detect susceptibility before symptoms appear, empowering individuals to take preventive measures. - Surge in Consumer Genomics
The consumer genomics segment is booming, with DTC kits providing easy access to genetic information. This growth is supported by the proliferation of companies offering nutrigenomics, fitness genetics, skin health, and longevity profiling services. - Technological Advancements in Genetic Sequencing
Decreasing costs of genome sequencing and improvements in bioinformatics and data interpretation have significantly expanded the market reach and diagnostic accuracy of genetic tests. - Rising Chronic Disease Burden
Health forecasts indicate a rising incidence of heart disease, diabetes, and neurodegenerative disorders—conditions strongly linked to genetic predisposition. For instance:
- Diabetes prevalence is expected to rise from 500 million (2023) to over 700 million by 2045 (IDF).
- Alzheimer’s cases may triple to nearly 18 million in the U.S. by 2060 (Alzheimer’s Association).
- The American Heart Association predicts over 60% of U.S. adults may suffer from heart disease or stroke by 2050.
These staggering projections are driving demand for early genetic risk assessments.
Predictive Genetic Testing & Consumer/Wellness Genomics Market Segmentation Analysis
By Test Type:
- Predictive Testing (2023 Share: ~40%)
Dominates due to applications in cancer, cardiovascular diseases, and neurological disorders. Enables targeted prevention and treatment strategies. - Consumer Genomics
Expected to grow at 15%+ CAGR, driven by DTC testing and growing public awareness. Utilized for wellness optimization, ancestry, and lifestyle planning.
By Application:
- Breast and Ovarian Cancer Screening
Accounted for ~30% market share in 2023. Tests such as BRCA1/2 help detect hereditary cancer risks and guide preventive decisions. - Cardiovascular Screening
Fastest-growing segment. Rising global burden of heart disease and stroke is propelling interest in cardiac genetic testing.
For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ https://www.snsinsider.com/request-analyst/2445
Regional Outlook
North America:
Largest market in 2023. The U.S. leads due to high awareness, FDA-approved DTC tests (e.g., 23andMe, AncestryDNA), and strong healthcare infrastructure. Personalized medicine is a well-integrated part of clinical workflows.
Europe:
Second-largest region. Countries like the UK and Germany offer publicly funded genetic testing programs. National health systems promote genomics as part of population health management.
Asia-Pacific:
Fastest-growing region, with projected CAGR exceeding 20%. Rising disposable income, urban health awareness, and government-backed genomic research in India and China are transforming access to personalized healthcare
Competitive Landscape
Key players in the predictive genetic testing & consumer/wellness genomics market include:
- 23andMe, Inc. – Personal Genome Service
- Myriad Genetics, Inc. – EndoPredict, Prolaris
- F. Hoffmann-La Roche Ltd – FoundationOne CDx
- Abbott – BRCA Analysis
- Agilent Technologies, Inc. – SureSelect
- Thermo Fisher Scientific Inc. – Ion Torrent, NovaSeq, MiSeq
- Illumina, Inc. – AmpliSeq, TruGenome
- BGI – CytoScan
- Bio-Rad Laboratories, Inc. – GeneSight
- Guardant Health, Inc. – Guardant360
- Color Genomics, Inc. – Color Test
- Hologic, Inc. (Gen-Probe) – Aptima
- Ambry Genetics (Konica Minolta) – Testing Services
- Quest Diagnostics – Hereditary Cancer Testing
- Mapmygenome, Xcode Life, EasyDNA, Orig3n, and Gene by Gene – DTC and clinical testing providers
Read Our Related Report:
Recent Developments
- August 2024: Myriad Genetics sold its EndoPredict unit to Eurobio Scientific, granting global rights for Prolaris IVD kits (excluding U.S.), expanding its reach in breast cancer diagnostics.
- July 2024: 23andMe launched a collaborative Lung Cancer Genetics Study with 20 U.S. advocacy organizations, aiming to improve early detection and personalized treatment strategies based on genomic data.
About US
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
